OR WAIT null SECS
Trudhesa was approved in September to treat migraine.
Impel NeuroPharma has partnered with Carepoint Pharmacy and Phil Inc. to dispense Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine with or without aura in adults.
The FDA approved Trudhesa September 2, 2021. It uses Impel’s proprietary precision olfactory delivery technology to deliver the therapy quickly to the bloodstream through the vascular-rich upper nasal space. Trudhesa bypasses the gut and potential absorption issues, offering rapid, sustained, and consistent symptom relief without injection or infusion, even when administered hours after the onset of a migraine attack.
Carepoint and Phil are full-service independent specialty pharmacy servicing patients, physicians, and providers nationwide. They offer an alternative to traditional access and distribution options.
“Our company was built to provide patients with a simple and patient-first pharmacy experience that makes getting prescriptions easy, fast and reliable,” Bhavesh Patel, Pharm.D., chief executive officer of Carepoint Pharmacy, said in a statement.
The wholesale acquisition cost (WAC) of Trudhesa will be $850 per pack of four doses. "We believe this price will be very competitive with the newer gepant products, which are priced on a comparable level in the $890 range,” Adrian Adams, chairman and CEO of Impel NeuroPharma, told Formulary Watch when Trudhesa received FDA approval.
According to one study, the prevalence of migraine and severe headache in the United States has remained stable. In 2018, the age-adjusted prevalence was 15.9% across all adults.